CClinicalTrials.gg
CompletedNCT04206670Updated May 10, 2022Results posted

In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment

An interventional study of In-Home Technology System and Questionnaires and Waiting Control In-Home Technology System and Questionnaires in Dementia, Mild Cognitive Impairment and Alzheimer Disease, sponsored by University of California, Berkeley. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-10.

Sponsored by University of California, Berkeley · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to develop and evaluate new in-home supportive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease, other dementias, or mild cognitive impairment.

Read the detailed description

This study aims to develop, refine, and evaluate a new hardware/software system designed to integrate in-home sensors and devices, Internet-of-Things technologies (i.e., devices that can be controlled and communicated with via the internet), and social networking to create a more safe and supportive home environment for caregivers and people who have Alzheimer's disease, other dementias, or mild cognitive impairment. The system monitors troublesome behaviors in people with dementia or mild cognitive impairment (e.g., wandering), and targets mechanisms (e.g., worry, social isolation) thought to link behavioral symptoms in people with dementia or mild cognitive impairment with adverse caregiver outcomes (declines in health and well-being). The system is designed to minimize demands on caregivers' limited time and energy and to provide a platform for data collection that can be used by researchers and care professionals.

Hypotheses:

  1. Caregivers in the full operation condition will have fewer negative effects of caregiving (lower burden, better mental and physical health, higher well-being) than those in the control condition.
  2. Greater use of the social networking features of the system will be associated with fewer caregiver depressive symptoms.
  3. Greater utilization of the home safety features of the system will be associated with fewer caregiver anxiety symptoms.
02

Conditions studied

  • Dementia
  • Mild Cognitive Impairment
  • Alzheimer Disease

Keywords

  • Caregivers
  • Dementia
  • Mild Cognitive Impairment
  • In-Home Technology
  • Alzheimer Disease
03

In context

Alzheimer Disease

3,678 studies on the registry are indexed under Alzheimer Disease; 872 are open to participants now.

This study's enrollment of 216 is above the median of 70 across 2,808 interventional studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

University of California, Berkeley is the lead sponsor of 106 studies on the registry; 18 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Caregivers are fluent/literate in English
  • Caregivers currently reside with spouse/family member who has received a diagnosis of Alzheimer's disease, other dementias, or mild cognitive impairment
  • Caregivers primarily use a smartphone (e.g., iPhone, Android)
  • Caregiver has wireless internet in home

Exclusion criteria

Exclusion Criteria:

  • Caregivers providing care for individuals with known non-neurodegenerative conditions affecting behavior and cognition
  • Caregivers providing care for individuals with longstanding Axis I psychiatric disorder
  • Caregivers providing care for individuals with metabolic disorder or major organ dysfunction
  • Caregivers providing care for individuals with alcohol abuse or dependence (within 5 years of dementia onset)
  • Caregivers providing care for individuals with head trauma with loss of consciousness greater than 30 minutes
  • Caregivers providing care for individuals with contraindications to MRI imaging
  • Caregivers providing care for individuals with large confluent white matter lesions
  • Caregivers providing care for individuals with significant systemic medical illness
  • Caregivers providing care for individuals who use a medication likely to affect central nervous system functions adversely
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
216 participants (actual)

Study arms

  • Experimental
    In-Home Technology System

    Participants will receive and install the full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) in their homes. Remote assistance will be provided to help with the installation. Sensors, warnings, messaging, and social networking features will be activated remotely. Participation will extend over a six month period with questionnaires (e.g., health and well-being) administered 3 times (at the time of installation and every 3 months thereafter).

    Device: In-Home Technology System and Questionnaires

  • Other
    Waiting Control

    Participants will be assigned a date for receiving and installing the full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) six months after they enter the study. During that six-month period, questionnaires (e.g., health and well-being) will be administered 3 times (at the start of the study and every 3 months thereafter). At the end of the six-month period, participants will receive and install the full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) in their homes. Remote assistance will be provided to help with the installation. Sensors, warnings, messaging, and social networking features will be activated remotely. Participation will extend over an additional six-month period with questionnaires (e.g., health and well-being) administered 2 times (every 3 months following installation).

    Device: Waiting Control In-Home Technology System and Questionnaires

Interventions

  • DeviceIn-Home Technology System and Questionnaires

    Participants self-install the in-home technology system in their homes after enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.

  • DeviceWaiting Control In-Home Technology System and Questionnaires

    Participants self-install the in-home technology system in their homes six months after their enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.

06

What researchers measure

Primary outcomes

  1. 3 Months Assessment for Center for Epidemiological Studies Depression Scale (CES-D)

    Questionnaire to measure depression (Radloff, 1977). 20 items are rated on a 0-3 scale and summed (range = 0-60). There are no subscales. Higher scores represent worse outcomes. The clinical cut-off is usually set at a score of 16.

    Time frame: 3 months after baseline

  2. 6 Months Assessment for Center for Epidemiological Studies Depression Scale (CES-D)

    Questionnaire to measure depression (Radloff, 1977). 20 items are rated on a 0-3 scale and summed (range = 0-60). There are no subscales. Higher scores represent worse outcomes. The clinical cut-off is usually set at a score of 16.

    Time frame: 6 months after baseline

  3. 3 Months Assessment for Zarit Burden Interview-Short Form

    Questionnaire to measure caregiver burden (Zarit, Reever, \& Bach-Peterson, 1980). 12 items are rated on 0-4 scale. Range: 0-48. No subscales. Higher scores represent worse outcomes.

    Time frame: 3 months after baseline

  4. 6 Months Assessment for Zarit Burden Interview-Short Form

    Questionnaire to measure caregiver burden (Zarit, Reever, \& Bach-Peterson, 1980). 12 items are rated on 0-4 scale. Range: 0-48. No subscales. Higher scores represent worse outcomes.

    Time frame: 6 months after baseline

  5. 3 Months Assessment for Beck Anxiety Inventory (BAI)

    Questionnaire to measure anxiety (Beck, Epstein, Brown, \& Steer, 1988). 20 items are rated on a 0-3 scale and summed (range= 0-60). Higher scores indicate worse outcomes. There are no subscales. A score greater than 36 is considered to be clinically significant.

    Time frame: 3 months after baseline

  6. 6 Months Assessment for Beck Anxiety Inventory (BAI)

    Questionnaire to measure anxiety (Beck, Epstein, Brown, \& Steer, 1988). 20 items are rated on a 0-3 scale and summed (range= 0-60). Higher scores indicate worse outcomes. There are no subscales. A score greater than 36 is considered to be clinically significant.

    Time frame: 6 months after baseline

  7. 3 Months Assessment for Satisfaction With Life Scale

    Questionnaire measuring overall life satisfaction and well-being (Diener, Emmons, Larsen, \& Griffin, 1985). 5 items scored on a 1-7 scale and summed (Range = 5-35). Lower scores indicate worse outcomes. A score of 20 is considered neutral with higher scores considered increasingly more satisfied and lower scores considered increasingly more dissatisfied.

    Time frame: 3 months after baseline

  8. 6 Months Assessment for Satisfaction With Life Scale

    Questionnaire measuring overall life satisfaction and well-being (Diener, Emmons, Larsen, \& Griffin, 1985). 5 items scored on a 1-7 scale and summed (Range = 5-35). Lower scores indicate worse outcomes. A score of 20 is considered neutral with higher scores considered increasingly more satisfied and lower scores considered increasingly more dissatisfied.

    Time frame: 6 months after baseline

07

Results

Posted May 10, 2022
Limitations and caveats
The study intended to recruit 400 participants, however at the start of enrollment, COVID-19 shutdowns occurred and caregivers were less likely to enroll in the study because they were at home (i.e., not out in public) more often, thus not needing to remotely monitor the individuals that they were providing care for. Thus the final number of installations was 216. Due to selective attrition the final active control ratio was approximately 2:1.

Participant flow

Participant flow — Overall Study
MilestoneIn-Home Technology SystemWaiting Control
Started14868
Completed12465
Not completed243

Outcome measures

Primary3 Months Assessment for Center for Epidemiological Studies Depression Scale (CES-D)

Questionnaire to measure depression (Radloff, 1977). 20 items are rated on a 0-3 scale and summed (range = 0-60). There are no subscales. Higher scores represent worse outcomes. The clinical cut-off is usually set at a score of 16.

Time frame:
3 months after baseline
Reported as:
Mean · units on a scale
3 Months Assessment for Center for Epidemiological Studies Depression Scale (CES-D)
units on a scaleIn-Home Technology SystemWaiting Control
3 Months Assessment for Center for Epidemiological Studies Depression Scale (CES-D)16.05 ± 10.3018.39 ± 10.27
Primary6 Months Assessment for Center for Epidemiological Studies Depression Scale (CES-D)

Questionnaire to measure depression (Radloff, 1977). 20 items are rated on a 0-3 scale and summed (range = 0-60). There are no subscales. Higher scores represent worse outcomes. The clinical cut-off is usually set at a score of 16.

Time frame:
6 months after baseline
Reported as:
Mean · units on a scale
6 Months Assessment for Center for Epidemiological Studies Depression Scale (CES-D)
units on a scaleIn-Home Technology SystemWaiting Control
6 Months Assessment for Center for Epidemiological Studies Depression Scale (CES-D)15.98 ± 11.6117.17 ± 9.55
Primary3 Months Assessment for Zarit Burden Interview-Short Form

Questionnaire to measure caregiver burden (Zarit, Reever, \& Bach-Peterson, 1980). 12 items are rated on 0-4 scale. Range: 0-48. No subscales. Higher scores represent worse outcomes.

Time frame:
3 months after baseline
Reported as:
Mean · units on a scale
3 Months Assessment for Zarit Burden Interview-Short Form
units on a scaleIn-Home Technology SystemWaiting Control
3 Months Assessment for Zarit Burden Interview-Short Form20.40 ± 9.1921.31 ± 8.63
Primary6 Months Assessment for Zarit Burden Interview-Short Form

Questionnaire to measure caregiver burden (Zarit, Reever, \& Bach-Peterson, 1980). 12 items are rated on 0-4 scale. Range: 0-48. No subscales. Higher scores represent worse outcomes.

Time frame:
6 months after baseline
Reported as:
Mean · units on a scale
6 Months Assessment for Zarit Burden Interview-Short Form
units on a scaleIn-Home Technology SystemWaiting Control
6 Months Assessment for Zarit Burden Interview-Short Form20.93 ± 9.1721.87 ± 8.86
Primary3 Months Assessment for Beck Anxiety Inventory (BAI)

Questionnaire to measure anxiety (Beck, Epstein, Brown, \& Steer, 1988). 20 items are rated on a 0-3 scale and summed (range= 0-60). Higher scores indicate worse outcomes. There are no subscales. A score greater than 36 is considered to be clinically significant.

Time frame:
3 months after baseline
Reported as:
Mean · units on a scale
3 Months Assessment for Beck Anxiety Inventory (BAI)
units on a scaleIn-Home Technology SystemWaiting Control
3 Months Assessment for Beck Anxiety Inventory (BAI)8.06 ± 7.719.29 ± 7.55
Primary6 Months Assessment for Beck Anxiety Inventory (BAI)

Questionnaire to measure anxiety (Beck, Epstein, Brown, \& Steer, 1988). 20 items are rated on a 0-3 scale and summed (range= 0-60). Higher scores indicate worse outcomes. There are no subscales. A score greater than 36 is considered to be clinically significant.

Time frame:
6 months after baseline
Reported as:
Mean · units on a scale
6 Months Assessment for Beck Anxiety Inventory (BAI)
units on a scaleIn-Home Technology SystemWaiting Control
6 Months Assessment for Beck Anxiety Inventory (BAI)7.81 ± 8.448.71 ± 6.53
Primary3 Months Assessment for Satisfaction With Life Scale

Questionnaire measuring overall life satisfaction and well-being (Diener, Emmons, Larsen, \& Griffin, 1985). 5 items scored on a 1-7 scale and summed (Range = 5-35). Lower scores indicate worse outcomes. A score of 20 is considered neutral with higher scores considered increasingly more satisfied and lower scores considered increasingly more dissatisfied.

Time frame:
3 months after baseline
Reported as:
Mean · units on a scale
3 Months Assessment for Satisfaction With Life Scale
units on a scaleIn-Home Technology SystemWaiting Control
3 Months Assessment for Satisfaction With Life Scale21.26 ± 6.9618.68 ± 7.11
Primary6 Months Assessment for Satisfaction With Life Scale

Questionnaire measuring overall life satisfaction and well-being (Diener, Emmons, Larsen, \& Griffin, 1985). 5 items scored on a 1-7 scale and summed (Range = 5-35). Lower scores indicate worse outcomes. A score of 20 is considered neutral with higher scores considered increasingly more satisfied and lower scores considered increasingly more dissatisfied.

Time frame:
6 months after baseline
Reported as:
Mean · units on a scale
6 Months Assessment for Satisfaction With Life Scale
units on a scaleIn-Home Technology SystemWaiting Control
6 Months Assessment for Satisfaction With Life Scale21.28 ± 7.5118.66 ± 7.06

Adverse events

Collected over Baseline to 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
In-Home Technology System0/148 (0%)0/148 (0%)0/148 (0%)
Waiting Control0/68 (0%)0/68 (0%)0/68 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)In-Home Technology SystemWaiting ControlTotal
Mean63.7 ± 11.864.6 ± 9.863.9 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)In-Home Technology SystemWaiting ControlTotal
Female9051141
Male581775
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)In-Home Technology SystemWaiting ControlTotal
Black or African American8311
East Asian, South Asian, Southeast Asian, or Indian American9413
Latino or Hispanic American8412
Native Hawaiian or Pacific Islander112
Non-Hispanic White or European American10851159
Other14519
Beck Anxiety Inventory
Beck Anxiety Inventory(units on a scale)In-Home Technology SystemWaiting ControlTotal
Mean7.36 ± 8.239.46 ± 7.128.02 ± 7.94
Zarit Burden Inventory
Zarit Burden Inventory(units on a scale)In-Home Technology SystemWaiting ControlTotal
Mean20.04 ± 8.7121.35 ± 8.1320.45 ± 8.53
Satisfaction with Life
Satisfaction with Life(units on a scale)In-Home Technology SystemWaiting ControlTotal
Mean20.99 ± 7.2418.81 ± 6.8520.30 ± 7.18
Center for Epidemiologic Studies Depression Scale
Center for Epidemiologic Studies Depression Scale(units on a scale)In-Home Technology SystemWaiting ControlTotal
Mean15.14 ± 10.0417.90 ± 10.4416.01 ± 10.22
08

Study locations

1 site
  • University of California, Berkeley
    Berkeley, California 94720, United States
09

References and documents

Publications

  • Chen KH, Wells JL, Otero MC, Lwi SJ, Haase CM, Levenson RW. Greater Experience of Negative Non-Target Emotions by Patients with Neurodegenerative Diseases Is Related to Lower Emotional Well-Being in Caregivers. Dement Geriatr Cogn Disord. 2017;44(5-6):245-255. doi: 10.1159/000481132. Epub 2017 Dec 8. PubMed 29216633 ↗
  • Lwi SJ, Ford BQ, Casey JJ, Miller BL, Levenson RW. Poor caregiver mental health predicts mortality of patients with neurodegenerative disease. Proc Natl Acad Sci U S A. 2017 Jul 11;114(28):7319-7324. doi: 10.1073/pnas.1701597114. Epub 2017 Jun 27. PubMed 28655841 ↗
  • Otero MC, Levenson RW. Lower Visual Avoidance in Dementia Patients Is Associated with Greater Psychological Distress in Caregivers. Dement Geriatr Cogn Disord. 2017;43(5-6):247-258. doi: 10.1159/000468146. Epub 2017 Apr 11. PubMed 28395276 ↗
  • Brown CL, Lwi SJ, Goodkind MS, Rankin KP, Merrilees J, Miller BL, Levenson RW. Empathic Accuracy Deficits in Patients with Neurodegenerative Disease: Association with Caregiver Depression. Am J Geriatr Psychiatry. 2018 Apr;26(4):484-493. doi: 10.1016/j.jagp.2017.10.012. Epub 2017 Dec 27. PubMed 29289452 ↗

Study documents

  • Study protocol · Apr 14, 2022
  • Statistical analysis plan · Apr 14, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Because health and other protected data are involved, we need to consult with our institutional review board and other collaborators concerning which data can be shared.

Supporting information: Study protocol, Icf

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04206670
Lead sponsor
University of California, Berkeley
Collaborators
People Power Company, National Institute on Aging (NIA), University of California, San Francisco
Responsible party
Robert Levenson (Professor, University of California, Berkeley) — Principal investigator
First posted
Dec 20, 2019
Start date
Mar 10, 2020
Primary completion
Dec 8, 2021
Completion
Dec 8, 2021
Results posted
May 10, 2022
Last update
May 10, 2022

Study contacts

Robert W Levenson, Ph.D.
study director · University of California, Berkeley

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion